## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.13 indicates fundamental undervaluation. Quality metrics strong (ROE 34%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-5.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($198.57)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 2)

**1. Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder**
- Source: Yahoo Finance Singapore | 20251223T041759 | Bearish | Relevance: 100%
- A Baltimore city jury awarded Cherie A. Craft over $1.5 billion after finding Johnson & Johnson liable for her mesothelioma, caused by asbestos in their talc-based personal care products. The verdict includes $59.84 million in compensatory damages and $1.5 billion in punitive damages against J&J and Pecos River Talc. This is believed to be the largest single-plaintiff verdict ever against Johnson & Johnson.

**2. Does Johnson & Johnson’s 2025 Rally Still Offer Value After Strong DCF and PE Signals?**
- Source: Simply Wall Street | 20251222T090755 | Bullish | Relevance: 100%
- This article analyzes Johnson & Johnson's stock performance and valuation indicators, including Discounted Cash Flow (DCF) and Price to Earnings (PE) ratios. Despite a significant rally in 2025, the analysis suggests J&J appears undervalued by these metrics, with a DCF model indicating a 46.3% undervaluation. The article also introduces "Narratives," a tool for investors to connect their market views to forecasts and fair value estimates.

**3. FDA confirms new recall for Johnson & Johnson heart device over safety concerns**
- Source: Cardiovascular Business | 20251223T160817 | Bearish | Relevance: 100%
- The FDA has issued a Class I recall for Johnson & Johnson MedTech’s Automated Impella Controllers (AICs) due to potential connectivity issues that could lead to inadequate hemodynamic support and serious injury or death. While not a product removal, customers must review updated instructions and have a backup AIC available. The company reported a 0.02% occurrence rate between January 2021 and May 2025, with these issues linked to three patient deaths.

**4. Tim Schmid shares Johnson & Johnson MedTech’s growth playbook**
- Source: Medical Design & Outsourcing | 20251222T140323 | Somewhat-Bullish | Relevance: 99%
- Tim Schmid, EVP and global medtech chairman of Johnson & Johnson MedTech, outlines the company's new growth strategy, which includes spinning off DePuy Synthes to focus on cardiovascular, surgery, and vision. This strategic shift, bolstered by acquisitions like Abiomed and Shockwave Medical, aims to increase J&J MedTech's presence in high-growth markets and improve its financial performance. Schmid also discusses the future of J&J's surgical robotics (Ottava), vision business, and ongoing M&A and R&D investments.

**5. Alvotech/Advanz First to Launch Golimumab Biosimilar Worldwide**
- Source: Pearce IP | 20251223T050831 | Somewhat-Bullish | Relevance: 74%
- Alvotech and Advanz have launched Gobivaz® (AVT05), the first golimumab biosimilar to be marketed globally, in Europe. This biosimilar to Janssen’s Simponi® received European and UK approval in November 2025 after its MAA was the first of its kind accepted worldwide in November 2024. While commercialization progresses across Europe, Alvotech is also working to resolve FDA deficiencies for AVT05 in the US following a Complete Response Letter in November 2025.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Goldman Sachs | $240 | $213 | +13% |
| 2025-12-15 | B of A Securiti | $220 | $204 | +8% |
| 2025-12-12 | Morgan Stanley | $197 | $190 | +4% |
| 2025-12-11 | Citigroup | $232 | $215 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Goldman Sachs | main | Buy |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($3.81M) |
| Sells | 6 ($0.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 7 raises (avg +9%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.13 suggests fair value with growth premium. Forward P/E 17.8x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (7 raises, avg +9%). Insider buying signal ($3.8M), management confidence. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $495.8B |
| Beta | 0.35 |
| 52W Range | $140.68 - $215.19 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.13 |
| Forward P/E | 17.8 |
| Current P/E | 18.9 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.2% to -1.4% (-5.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.4pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-0.68), momentum weakening. RSI neutral at 53. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.43% (CS: 38) | Neutral |
| RSI_14 | 53.3 | Neutral |
| MACD Histogram | -0.68 | Bearish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 1.037x | Above |
| vs SMA200 | 1.191x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $205.77
- **Stop Loss:** $198.57 (3.5% risk)
- **Target:** $220.17 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 166
- **Position Value:** $34,157.82
- **Portfolio %:** 34.16%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*